000070283 001__ 70283
000070283 005__ 20190709135605.0
000070283 0247_ $$2doi$$a10.1186/s13287-018-0843-z
000070283 0248_ $$2sideral$$a105907
000070283 037__ $$aART-2018-105907
000070283 041__ $$aeng
000070283 100__ $$0(orcid)0000-0002-2898-4561$$aRando, A.
000070283 245__ $$aIntramuscular transplantation of bone marrow cells prolongs the lifespan of SOD1G93A mice and modulates expression of prognosis biomarkers of the disease
000070283 260__ $$c2018
000070283 5060_ $$aAccess copy available to the general public$$fUnrestricted
000070283 5203_ $$aBackground: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive muscle weakness, paralysis and death. There is no effective treatment for ALS and stem cell therapy has arisen as a potential therapeutic approach. 
Methods: SOD1 mutant mice were used to study the potential neurotrophic effect of bone marrow cells grafted into quadriceps femoris muscle. 
Results: Bone marrow intramuscular transplants resulted in increased longevity with improved motor function and decreased motoneuron degeneration in the spinal cord. Moreover, the increment of the glial-derived neurotrophic factor and neurotrophin 4 observed in the grafted muscles suggests that this partial neuroprotective effect is mediated by neurotrophic factor release at the neuromuscular junction level. Finally, certain neurodegeneration and muscle disease-specific markers, which are altered in the SOD1G93A mutant mouse and may serve as molecular biomarkers for the early detection of ALS in patients, have been studied with encouraging results. 
Conclusions: This work demonstrates that stem cell transplantation in the muscle prolonged the lifespan, increased motoneuron survival and slowed disease progression, which was also assessed by genetic expression analysis.
000070283 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/RD16-001-0010$$9info:eu-repo/grantAgreement/ES/MINECO/SEV-2013-0317
000070283 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000070283 590__ $$a4.627$$b2018
000070283 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b30 / 135 = 0.222$$c2018$$dQ1$$eT1
000070283 591__ $$aCELL BIOLOGY$$b59 / 191 = 0.309$$c2018$$dQ2$$eT1
000070283 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000070283 700__ $$aPastor, D.
000070283 700__ $$aViso-León, M.C.
000070283 700__ $$aMartínez, A.
000070283 700__ $$aManzano, R.$$uUniversidad de Zaragoza
000070283 700__ $$aNavarro, X.
000070283 700__ $$0(orcid)0000-0001-5687-6704$$aOsta, R.$$uUniversidad de Zaragoza
000070283 700__ $$aMartínez, S.
000070283 7102_ $$11001$$2420$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Genética
000070283 773__ $$g9, 1 (2018), 90 [12 pp]$$pSTEM CELL RESEARCH & THERAPY$$tSTEM CELL RESEARCH & THERAPY$$x1757-6512
000070283 8564_ $$s3401789$$uhttp://zaguan.unizar.es/record/70283/files/texto_completo.pdf$$yVersión publicada
000070283 8564_ $$s102440$$uhttp://zaguan.unizar.es/record/70283/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000070283 909CO $$ooai:zaguan.unizar.es:70283$$particulos$$pdriver
000070283 951__ $$a2019-07-09-12:19:45
000070283 980__ $$aARTICLE